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ABSTRACT Despite the great increase in the understanding of the biology and
pathogenesis of Mycobacterium tuberculosis achieved by the scientific community
in recent decades, tuberculosis (TB) still represents one of the major threats to
global human health. The only available vaccine (Mycobacterium bovis BCG) pro-
tects children from disseminated forms of TB but does not effectively protect
adults from the respiratory form of the disease, making the development of new
and more-efficacious vaccines against the pulmonary forms of TB a major goal
for the improvement of global health. Among the different strategies being de-
veloped to reach this goal is the construction of attenuated strains more effica-
cious and safer than BCG. We recently showed that a sigE mutant of M. tubercu-
losis was more attenuated and more efficacious than BCG in a mouse model of
infection. In this paper, we describe the construction and characterization of an
M. tuberculosis sigE fadD26 unmarked double mutant fulfilling the criteria of the
Geneva Consensus for entering human clinical trials. The data presented suggest
that this mutant is even more attenuated and slightly more efficacious than the
previous sigE mutant in different mouse models of infection and is equivalent to
BCG in a guinea pig model of infection.
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Tuberculosis (TB) is a complex disease still considered one of the major threats toglobal human health. Even though it is a curable disease, its control poses a great
challenge to the health care systems of countries with high TB incidence, due to the
length of treatment, the difficulty of obtaining compliance, and the circulation of
multidrug-resistant strains. The only available vaccine against TB, the attenuated strain
of Mycobacterium bovis BCG, is effective in protecting children from disseminated forms
of the disease but not in protecting adults from its pulmonary form; thus, it does not
interrupt the Mycobacterium tuberculosis transmission chain (1). Recently, the scientific
community has developed different vaccine candidates and vaccination strategies,
approaching the challenge of developing a new vaccine against TB either as a prime
vaccine that could replace BCG or as a booster for individuals previously vaccinated
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with BCG (2). A leading strategy is focused on the development of attenuated myco-
bacterial strains that are more efficient in eliciting protective immunity than BCG (3, 4).
To achieve this goal, different approaches have been used, including the construction
of recombinant strains of BCG that can express additional protective antigens not
encoded in its genome (5–7) or that can evade the phagosome, thus facilitating antigen
presentation (8), and the use of attenuated M. tuberculosis strains, which inherently
express a broader repertoire of mycobacterial antigens (9, 10).
Previously, we showed that an M. tuberculosis sigE-null mutant was strongly atten-
uated and conferred better protection from aerosol infection with M. tuberculosis than
BCG in both mice and guinea pigs (11, 12). SigE, one of ten extracytoplasmic function
(ECF) sigma factors encoded in the M. tuberculosis genome (13), is subject to very
complex regulation (14, 15). It has been shown to be involved in setting the basal level
of sensitivity to several TB drugs (16) and in the development of persisters that are able
to escape drug bactericidal activity (16), and it is essential for virulence in macrophages
(17), mice (18), and guinea pigs (12). The precise mechanism behind these phenotypes
is still not known, but the failure to maintain surface homeostasis and possibly
remodeling of its surface composition in response to surface stress might play impor-
tant roles (13, 17, 19). Moreover, SigE has been shown to be required for blocking
phagosome maturation, thus leading to more-efficient antigen presentation (20).
To begin the development of a new mutant that fulfills the Geneva Consensus
requirements for entering human clinical trials (21, 22), we recently constructed a new
M. tuberculosis sigE-null mutant, designated ST218, in which the entire copy of the gene
was deleted and which lacked any resistant marker (20). In this article, we describe a
further evolution of this strain, into which we introduced a second unmarked mutation
by deleting fadD26, a gene essential for virulence, whose product is involved in the
biosynthesis of phthiocerol dimycocerosates (23). This new TB vaccine candidate was
shown to be more attenuated and more protective than BCG; thus, it is a promising
new prime TB vaccine candidate in the pipeline.
RESULTS
Construction of a double unmarked sigE fadD26 mutant in M. tuberculosis.
Using a two-step procedure based on the suicide plasmid pAZ5 (9), the fadD26 gene
was replaced by a Hyg cassette flanked by res sites in the unmarked sigE-null mutant
ST218 (see Fig. S1 in the supplemental material) (20). The Hyg cassette was then
removed to produce a double unmarked sigE fadD26 mutant that was named TB223
(see Materials and Methods).
The sigE fadD26 double mutant TB223 is more attenuated than BCG. One of the
requirements of the Geneva Consensus for an M. tuberculosis mutant to enter clinical
trials is that its attenuation must be comparable to that of BCG in relevant animal
models. To prove that TB223 fulfills this criterion, its virulence was compared with that
of BCG in SCID and nude mice. For this purpose, groups of 20 mice were infected by
subcutaneous inoculation at the base of the tail with one dose of 8,000 CFU of BCG or
TB223. Only 10% of the BCG-infected SCID mice were still alive after 5 weeks of
infection, compared to 90% of TB223-infected mice, but the survival of the latter was
reduced to only 10% after 9 additional weeks, suggesting greater sensitivity of TB223
than of BCG to innate immunity (Fig. 1A). In nude mice, the picture was slightly
different: TB223-infected mice survived until the 10th week of infection, after which
their survival started to decrease gradually. However, the survival of BCG-infected mice
decreased very rapidly starting from the 15th week of infection, and none of these mice
survived to week 19, when 60% of TB223-infected mice were still alive (Fig. 1B).
Comparison of the attenuation of the sigE fadD26 double mutant TB223 and
the sigE single mutant TB218. The virulence of the new double mutant was compared
with that of the sigE single mutant TB218 in BALB/c mice infected with a high bacterial
dose (2.5  105 CFU) by the intratracheal route. As shown in Fig. 2A, none of the mice
infected with wild-type (WT) H37Rv and 30% of the mice infected with TB218 were still
alive after 17 weeks of infection. However, the survival rate of the mice infected with
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the new double mutant at the same time point was 70%. Figure 2B shows the lung
bacterial burdens during the same experiment: after 21 days of infection, the numbers
of bacteria in the different groups were similar. However, after 60 days of infection, the
bacterial burdens detected in the lungs of mice infected with the WT strain showed a
FIG 1 Survival of SCID (A) or nude (B) mice (20 mice per strain) infected by the subcutaneous route in the base of
the tail (8,000 CFU) with M. tuberculosis TB223 or BCG. Survival curves were obtained by plotting the number of
surviving mice as a function of time using the Kaplan-Meier algorithm. The curves in panel A were statistically
different from each other (P  0.0009).
FIG 2 Comparisons of survival and bacillary loads for BALB/c mice infected intratracheally with different mycobacterial strains: the sigE mutant TB218, the sigE fadD26
double mutant TB223, and the parental strain H37Rv. (A) Survival curve constructed with 20 mice per strain. Kill curves were obtained by plotting the number of dying
mice as a function of time using the Kaplan-Meier algorithm. The survival of mice infected with the two different mutants did not differ statistically. However, the
survival of mice infected with wild-type H37Rv was different from that of mice infected with either of the two mutants (P, 0.0001 for H37Rv versus TB223 and 0.0095
for H37Rv versus TB218). (B) Bacterial burdens in the lungs. Mice were sacrificed at the indicated days after infection, and lungs (n , 4 per group per time point) were
used for the determination of CFU. At the later time points, mice infected with the double mutant TB223 showed significantly lower bacillary loads than the other
groups. Asterisks indicate statistical significance (*, P  0.05; **, P  0.01). n.s., not significant. (C) Quantitative expression of IFN- mRNA in lungs from mice infected
with H37Rv, TB218, or TB223 was determined by real-time PCR. Data are means and standard deviations of results from four different animals at each time point.
Asterisks indicate statistical significance for comparisons with H37Rv-infected mice (*, P  0.05; **, P  0.01).
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marked increase over those with the two mutant strains. After 120 days of infection,
mice infected with the sigE single mutant also showed a marked increase in lung
bacterial burdens, while those infected with the new double mutant were still able to
control the infection, suggesting a higher attenuation of the double mutant than of the
single mutant. It is worth noting that both sigE mutants were able to induce higher
levels of gamma interferon (IFN-) expression in the lungs of infected mice than their
parental strain H37Rv (Fig. 2C).
Comparative protection against M. tuberculosis in BALB/c mice vaccinated with
the sigE mutant TB218, the sigE fadD26 mutant TB223, or BCG. To compare the
levels of protection induced by BCG and the sigE mutants, groups of BALB/c mice (40
per group in 2 separate experiments) were vaccinated by subcutaneous inoculation at
the base of the tail with 8,000 CFU of the respective strain. At 60 days postvaccination,
mice were challenged intratracheally with 2.5  105 CFU of M. tuberculosis 5186. The
survival curves of the animals after infection, shown in Fig. 3A, clearly indicate that the
three strains protected the animals from death at comparable levels. However, when
we evaluated the bacterial burdens in the lungs and spleens of infected animals at 60
and 120 days postinfection (Fig. 3D and E), it was clear that the double mutant
protected better than the single mutant and BCG in both the lung and the spleen.
Areas of pneumonia in the lungs of infected mice were also measured, and mice
vaccinated with the double mutant showed less TB-associated pathology than those
vaccinated with the single mutant TB218 or with BCG (Fig. 3B; see also Fig. S2A in the
supplemental material). Finally, analysis of the sizes of granulomas in infected lungs
showed that mice vaccinated with the double mutant TB223 had larger granulomas
FIG 3 Survival, lung and spleen bacillary loads, and results of automated morphometry after intratracheal challenge with the highly virulent M. tuberculosis
Harlem genotype 5186 for BALB/c mice vaccinated with TB218, TB223, or BCG and for nonvaccinated control animals (SS). (A) Survival of the different groups
of BALB/c mice (20 mice per strain) vaccinated with the indicated strains. Survival curves were obtained by plotting the number of surviving mice as a function
of time using the Kaplan-Meier algorithm. The survival of vaccinated mice was statistically different from that of unvaccinated mice (P  0.0001), while the
survival of the animals vaccinated with the three different vaccines was not significantly different. (B) Percentage of the lung surface affected by pneumonia,
determined by automated morphometry. (C) Sizes of granulomas, measured by automated morphometry. (D and E) Bacillary loads in the lungs (D) and spleens
(E) of the different groups of BALB/c mice vaccinated with the indicated strains after 60 and 120 days postchallenge. The results are expressed as means 
standard deviations for four mice. Asterisks indicate statistical significance (*, P  0.05; **, P  0.01) for differences between groups. No data are presented for
the nonvaccinated control animals at 2 and 4 months postchallenge, since no surviving animals were available.
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after 120 days postinfection (Fig. 3C; also Fig. S2B). In this murine model, granuloma
size correlates with protection (24), so the larger granulomas confirmed the improved
protection conferred by the double mutant TB223.
Comparative protection against M. tuberculosis in C57BL/6 mice vaccinated
with the sigE fadD26 mutant TB223 or BCG. Protection was also evaluated in a
Beijing challenge model. To compare the levels of protection induced by BCG and the
sigE fadD26 mutant, groups of C57BL/6 mice were vaccinated subcutaneously. Six
weeks after immunization, mice were challenged with 200 CFU of M. tuberculosis Beijing
strain K via the aerosol route. After 4 and 8 weeks postinfection, mice were sacrificed.
TB223-immunized mice showed lower levels of pathology (inflammation) than nonim-
munized or BCG-immunized mice, especially at 8 weeks postinfection (Fig. 4A and B). In
gross pathology analysis, TB223 immunization showed the most effective protection at
8 weeks postinfection (Fig. 4C). These protective efficacies correlated with bacterial
burdens. TB223-vaccinated mice had significantly lower bacterial burdens than the
nonvaccinated control group and lower bacterial burdens than BCG-vaccinated mice in
both the lung and the spleen, although the latter difference did not reach statistical
significance (Fig. 4D and E), suggesting that TB223 has greater efficacy than BCG in the
C57BL/6 mouse model of infection with M. tuberculosis Beijing strain K.
Comparative protection against M. tuberculosis in guinea pigs vaccinated with
the sigE fadD26 mutant or BCG. Finally, the protective potential of the TB223 strain
FIG 4 Protective efficacy of BCG and TB223 immunization against infection with M. tuberculosis Beijing strain K. (A) H&E-stained sections (n, 6 mice/group) of
lungs from nonimmunized (Unvacc.), BCG-immunized, and TB223-immunized mice at 4 and 8 weeks after challenge with aerosolized M. tuberculosis Beijing
strain K (full-size images; bars, 2 mm). (B) Areas of lung inflammation, calculated using the ImageJ program (National Institutes of Health, USA). (C) Gross
pathology of lungs from nonimmunized, BCG-immunized, and TB223-immunized mice at 8 weeks after challenge. (D and E) Bacterial burdens in the lungs (D)
and spleens (E) of nonimmunized, BCG-immunized, and TB223-immunized mice at 4 and 8 weeks after infection with M. tuberculosis Beijing strain K. Data are
means and standard deviations of results for six mice. Asterisks indicate statistical significance (*, P  0.05; **, P  0.01; ***, P  0.001) for comparison with mice
infected with M. tuberculosis Beijing strain K.
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was compared to that of BCG in an established short-term (4-week) guinea pig infection
model. Animals were vaccinated once with 5  104 CFU by the subcutaneous route of
delivery and were infected with M. tuberculosis at week 12. As shown in Fig. 5, the level
of protection (as measured by the bacterial load) induced by TB223 in the lungs was
equivalent to that obtained with BCG (P  0.4), although TB223 was less protective than
BCG in the spleen (P  0.001).
DISCUSSION
In previous work, we demonstrated that an M. tuberculosis mutant missing the gene
encoding the alternative sigma factor SigE (ST28), beyond being severely attenuated,
induced strong IFN- and tumor necrosis factor alpha (TNF-) responses (11). When this
mutant was used to vaccinate mice or guinea pigs before challenge with virulent M.
tuberculosis, it was able to induce better protection than BCG (11, 12). In the original
mutant (ST28), sigE was disrupted by a cassette conferring hygromycin resistance,
ruling out the use of this construct in clinical trials. For this reason, we recently
constructed a new, unmarked sigE mutant in which the entire sigE gene was deleted
(20). To further improve the biosafety of this strain and to fulfill the Geneva Consensus
for entering clinical trials (21, 22), we introduced a second unmarked mutation, deleting
fadD26, into this strain. The deletion of this gene, whose product is required for the
biosynthesis of phthiocerol dimycocerosates and is essential for virulence, has already
been used successfully to improve the biosafety, without decreasing the protective
potential, of another candidate vaccine: the phoP fadD26 mutant MTBVAC, the first
attenuated M. tuberculosis mutant to be tested in clinical trials (9).
Despite its good safety profile, BCG vaccination can cause disseminated disease in
severely immunocompromised children (25), so one of the essential characteristics of a
new attenuated vaccine is a better attenuation profile (3, 7). In this study, we used
different mouse infection models to characterize the virulence of the sigE fadD26
double mutant and to compare it to those of the sigE single mutant and BCG.
First, we showed that the double mutant was more attenuated than BCG in both
nude and SCID mice (Fig. 1). Attenuation was more pronounced in SCID mice than in
nude mice. While SCID mice suffer severe humoral and cellular immunodeficiency,
humoral immunity is not affected in nude mice. Consequently, it is possible that nude
mice have sufficient antibody production, which can contribute to bacterial killing
facilitated by an antibody-mediated mechanism. Then we also demonstrated that the
FIG 5 Bacillary loads in the lungs (left) and spleens (right) of guinea pigs vaccinated with TB223 or BCG
Danish 1331, or in those of unvaccinated control animals, 4 weeks after aerosol challenge with M.
tuberculosis H37Rv. Animals were vaccinated once subcutaneously with 5  104 CFU in 250 l and were
challenged 12 weeks postvaccination. Bacterial load data are expressed as log10 total CFU. Bars, group
means (n  8); error bars, standard errors of the means. Asterisks indicate statistical significance (***,
P  0.001; n.s., not significant [P  0.05]) in comparison to either BCG-vaccinated or unvaccinated guinea
pigs.
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double mutant reached lower bacillary loads in the lungs of immunocompetent mice
than the sigE single mutant, suggesting higher attenuation for the former (Fig. 2).
The protection elicited by the double mutant was then characterized in two
different murine models and one guinea pig model of infection. In a previous report,
we showed that mice vaccinated with the single sigE mutant were more protected
against M. tuberculosis infection than mice vaccinated with BCG. Interestingly, the
difference from BCG was more evident when mice were challenged with a hyperviru-
lent strain of M. tuberculosis (11). For this reason, in the experiments described in this
paper, mice were challenged with highly virulent clinical strains and not with H37Rv. In
the first model, BALB/c mice vaccinated with either the sigE fadD26 double mutant or
the sigE single mutant were then challenged by intratracheal infection with M. tuber-
culosis Harlem 5186 (26, 27). After 2 months postinfection, only mice vaccinated with
the single mutant showed lung bacillary loads lower than those in BCG-vaccinated
mice, while animals vaccinated with either the double or the single mutant showed
decreased bacillary loads in their spleens. Interestingly, mice vaccinated with the
double mutant showed less lung pathology than BCG-vaccinated mice, even when the
lung bacillary loads of the animals belonging to the two groups were comparable. After
two additional months, the number of bacteria in the lungs of mice vaccinated with the
double mutant remained stable, while that in the lungs of mice vaccinated with the
single mutant or BCG increased to reach values statistically higher than those found in
the animals vaccinated with the double mutant. This finding suggested that the double
mutant conferred a more potent and longer-lasting protection than the other two
strains. Reduced bacterial loads correlated with improved survival rates. The groups of
animals vaccinated with BCG or the single mutant had equivalent survival rates, while
mice vaccinated with the double mutant had an improved survival rate, significantly
reduced TB-associated pathology, and larger granulomas. The observed increase in
efficacy correlated with relatively higher IFN- expression in BALB/c mice infected with
a high dose of the double mutant delivered by the intratracheal route.
In the second model, C57BL/6 mice were vaccinated either with the double mutant
or with BCG and were then challenged by the aerosol route with M. tuberculosis Lineage
2 Beijing strain K (28). In this case also, the double mutant was shown to induce slightly
better protection than BCG, suggesting that this vaccine candidate has potential utility
in East Asian countries, where the Beijing genotype is predominant in those vaccinated
with BCG.
In the guinea pig model, the sigE fadD26 double mutant of M. tuberculosis demon-
strated both safety and efficacy against aerosol challenge with M. tuberculosis H37Rv.
This vaccine gave protection equivalent to that of BCG in the lungs and may offer
advantages over BCG, such as the provision of a broader repertoire of protective
antigens and the generation of more M. tuberculosis-like responses without disease.
More studies are required in order to further understand the immune responses in
guinea pigs and to determine if this vaccine could be more efficacious in a revaccina-
tion regimen.
Live attenuated vaccines based on rational attenuation of M. tuberculosis are show-
ing promise in the preclinical space, and such candidates are currently in clinical trials
(e.g., MTBVAC). Here, we report an evaluation of the safety and protective efficacy of a
sigE fadD26 double mutant of M. tuberculosis. These results suggest that the sigE fadD26
mutant of M. tuberculosis could be used as an effective vaccine to replace or supple-
ment BCG in infants or adults with historic BCG vaccination who live in countries where
TB is endemic.
MATERIALS AND METHODS
Bacterial strains, growth media, and transformation conditions. The following bacterial strains
were used: Escherichia coli K-12 mc1061 (29) and E. coli XL1-Blue, M. tuberculosis TB218 (20), BCG Phipps
(30), BCG Pasteur (30), BCG Danish 1331 (31), M. tuberculosis Harlem 5186 (26, 27), and M. tuberculosis
Beijing K (28) (see Table S1 in the supplemental material). E. coli strains were grown at 37°C in
Luria-Bertani (LB) broth or on LB agar plates. Mycobacterial strains were grown at 37°C in Middlebrook
7H9 broth (Becton Dickinson [BD]) in 150-ml roller bottles with slow rotation (3 rpm) or on 7H10 agar
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plates (BD), supplemented with 0.2% glycerol and 0.05% Tween 80. For the growth of M. tuberculosis, the
medium was supplemented with 10% albumin, dextrose, and NaCl (ADN). When required, antibiotics or
sucrose were added to the medium at the following concentrations: kanamycin (Km), 50 g/ml; hygro-
mycin (Hyg), 150 mg/ml (E. coli) or 50 mg/ml (M. tuberculosis); sucrose (Suc), 2% (wt/vol).
Construction of an unmarked sigE fadD26 double mutant of M. tuberculosis. TB218 (20) was
electroporated with pAZ5 (9). Transformants were selected on Hyg-containing plates, and single colonies
were assayed for Suc sensitivity in order to select strains with the plasmid integrated by insertional
duplication (TB218::pAZ5). In the second step, 10 Hygr Sucs colonies (TB218::pAZ5 1 to TB218::pAZ5
10) were propagated in liquid medium to allow the second recombination event to occur, and serial
dilutions were plated onto Suc-containing plates to select bacteria that had lost the sacB gene. Hygr
Sucr clones were tested by PCR using two primers (RP1248 and RP1249) (Table S1 in the supplemental
material) internal to the fadD26 gene (Fig. S1A). As shown in Fig. S1B, no PCR product was amplified from
4 of the 10 clones tested, suggesting correct deletion of fadD26. These clones were further tested using
two different pairs of primers (RP1244 –RP1245 [primer pair A] and RP1246 –RP1247 [primer pair B])
(Table S1) hybridizing in the res sites or outside the fadD26-flanking regions cloned into pAZ5 (9) (Fig.
S1A). In the presence of a correct deletion of fadD26, we would expect to obtain a PCR product of 905 bp
from primer pair A and a band of 1,532 bp from primer pair B. As shown in Fig. S1C, all the strains gave
PCR products of the correct sizes, confirming the correct deletion of fadD26 in these strains. One of these
clones (clone 2.1) was named TB219 and was conserved for further studies.
Finally, plasmid pAZ20 (9) was introduced into TB219 to generate the unmarked fadD26 mutant.
pAZ20 expresses the tnpR gene under the control of promoter PblaF and includes the sacB gene, which
provides negative selection for the spontaneous loss of the helper plasmid when plated on a Suc-
containing medium. Transformants were selected on Km-containing plates, grown until saturation in
liquid medium, and plated onto Suc-supplemented plates. The clones obtained were tested by PCR using
primers RP1244 and RP1246 (Table S1 and Fig. S1A in the supplemental material). In the presence of a
correct deletion of fadD26, we would expect to obtain a PCR product of 2,633 bp, while no deletion
would result in an expected PCR product of 4,004 bp. As shown in Fig. S1D, a product of the correct size
was amplified from a clone (named TB223). The correct sequence of the fragment was finally confirmed
by Sanger sequencing (not shown).
Mouse infection and RNA extraction from lung homogenates. Male BALB/c mice, 8 to 10 weeks
old, were used to evaluate the virulence of strains by the determination of survival, pulmonary bacterial
loads, and TB pathology (pneumonia and granuloma size), and the immune response was evaluated by
measurement of the expression of gamma interferon (IFN-), as described previously (1). Briefly, bacilli
were grown in Middlebrook 7H9 liquid culture medium and were monitored by densitometry. As soon
as the culture reached mid-log phase, the bacilli were harvested and were suspended in phosphate-
buffered saline (PBS) containing 0.05% Tween 80 by shaking for 10 min with glass beads. Large clumps
of bacilli were removed from the suspension by centrifugation for 1 min at 350  g. Then a preliminary
bacterial count was achieved by smearing the supernatant at a known ratio of volume to area and
counting 10 random fields after Ziehl-Neelsen staining. The suspension was finally diluted to 2.5  105
CFU in 100 l of PBS and was aliquoted at –70°C. Before use, bacteria were recounted, and viability was
checked as described previously (22). To induce progressive pulmonary TB, mice were anesthetized with
sevoflurane and were inoculated intratracheally with 2.5  105 CFU of either M. tuberculosis H37Rv, the
sigE mutant (TB218), or the sigE fadD26 double mutant (TB223) suspended in 100 l PBS (15). After animal
infection, the remnant of the bacterial inoculum was plated onto solid agar to confirm the number of
CFU administered to the animals. Infected mice were kept in a vertical position until the effect of the
anesthesia had passed. Animals were maintained in groups of five in cages fitted with microisolators
under negative pressure. Ten mice from each group were left undisturbed so as to allow survival to be
recorded from day 8 up to week 32 after infection. Six animals from each group were sacrificed by
exsanguination at 21, 60, and 120 days after infection. Both lung lobes were snap-frozen in liquid
nitrogen and were then stored at –70°C for microbiological and immunological analysis (15). All
procedures were performed in a laminar flow cabinet in a biosafety level 3 facility. Two independent
experiments were performed.
To confirm the attenuation of the sigE mutants, groups of 10 SCID and nude mice were infected
subcutaneously at the base of the tail with one dose of 8,000 CFU of the live sigE mutant, double mutant,
or BCG substrain Phipps, and the survival of these mice was recorded. After animal infection, the remnant
of the bacterial inoculum was plated onto agar to confirm the number of CFU administered to the
animals (1).
Determination of CFU counts in infected lungs. Right lungs from four mice at each time point, in
two separate experiments, were used to determine bacterial burdens by colony counts on solid agar.
Lungs were homogenized with a Polytron homogenizer (Kinematica, Lucerne, Switzerland) in sterile
50-ml tubes containing 3 ml of isotonic saline. Four dilutions of each homogenate were spread onto
duplicate plates containing Bacto Middlebrook 7H10 agar (Difco Labs, Detroit, MI) enriched with oleic
acid-albumin-dextrose-catalase (OADC). Plates were incubated for 21 days prior to determination of CFU
counts (1).
Evaluation of protection of vaccinated BALB/c mice against infection with virulent M. tuber-
culosis Harlem 5186. Groups of 8-week-old BALB/c mice were vaccinated subcutaneously at the base of
the tail with 8,000 live bacilli of BCG substrain Phipps, the sigE mutant, or the sigE fadD26 double mutant.
At 60 days postvaccination, mice were challenged by the intratracheal route with 2.5  105 CFU of the
hypervirulent Harlem strain code 5186. This is a clinical strain collected from an epidemiological study in
the south of Mexico; it is highly virulent and transmissible in the community and in this murine model
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(26). The control group consisted of unvaccinated mice intratracheally infected with the same dose of
strain 5186. After 2 and 4 months postchallenge, protection was determined by the quantification of
bacterial CFU in lung and spleen homogenates and by automated morphometry, measuring TB pathol-
ogy in the lung affected by pneumonia and granuloma size. Ten further animals per group remained in
the study, were monitored until they reached a humane endpoint, and were then sacrificed. Deaths were
recorded in order to construct survival curves using the Kaplan-Meier algorithm (32). Two independent
experiments were performed.
Preparation of lung tissue for histology and automated morphometry. For histology and
automated morphometry, the left lobe of the lung was fixed by intratracheal perfusion with 4%
formaldehyde for 24 h and was then sectioned through the hilus and embedded in paraffin. Sections
(thickness, 5 m) were stained with hematoxylin and eosin (H&E) for the histological-morphometric
analysis. The percentage of the pulmonary area affected by pneumonia and the sizes (expressed as areas
in square micrometers) of granulomas were determined using an automated image analyzer (Leica QWin;
Leica, Milton Keynes, United Kingdom) (1). Granulomas are well-limited nodules constituted by lympho-
cytes and macrophages. From each lung, three serial sections, 100 m apart, were obtained. In each
section, all the granulomas were measured, and their areas in square micrometers were determined. To
determine the extent of pneumonia, each slide was photographed using a camera system that obtained
an image of the full lung area, corresponding to an area of 100%. Then the pneumonic areas were
delimited and measured with the software analyzer. Finally, the percentage of the lung surface area
affected by pneumonia was determined. Measurements were done blind, and the data are reported as
mean values  standard deviations (SD) from three different mice per group in two independent
experiments.
RT-PCR analyses. Left or right lung lobes from three different mice per group in two different
experiments were used to isolate mRNA using the RNeasy minikit (Qiagen) according to the recommen-
dations of the manufacturer. The quality and quantity of RNA were evaluated through spectrophotom-
etry (260/280 nm) and on agarose gels. Reverse transcription of the mRNA was performed using 5 g
RNA, oligo(dT), and the Omniscript kit (Qiagen, Inc.). Real-time PCR (RT-PCR) was carried out using the
7500 real-time PCR system (Applied Biosystems) and the QuantiTect SYBR green master mix kit (Qiagen).
Standard curves of the quantified and diluted PCR product, as well as negative controls, were
included in each PCR run. Specific primers for genes encoding acidic ribosomal protein (RLP0) as a
housekeeping gene (forward [FWD], 5=-CTCTCGCTTTCTGGAGGGTG-3=; reverse [RV], 5=-ACGCGCTTGTAC
CCATTGAT-3=) and IFN- (FWD, 5=-GGTGACATGAAAATCCTGCAG-3=; RV, 5=-CCTCAAACTTGGCAATACTCA
TGA-3=) were designed using the Primer Express program (Applied Biosystems). The cycling conditions
used were as follows: initial denaturation at 95°C for 15 min, followed by 40 cycles at 95°C for 20 s, 60°C
for 20 s, and 72°C for 34 s. Quantities of the specific mRNA in the sample were measured according to
the corresponding gene-specific standard. The mRNA encoding RLP0 was used as an internal invariant
control to normalize the expression of the IFN- gene. Data are shown as copies of cytokine-specific
mRNA per 106 copies of RLP0-specific mRNA (1).
Evaluation of protection against infection with M. tuberculosis Beijing strain K in vaccinated
C57BL/6 mice. M. tuberculosis strain K (28) was obtained from the strain collections at the Korean
Institute of Tuberculosis (KIT; Osong, Chungcheongbuk-do, South Korea). BCG (Pasteur 1173P2) was
kindly provided by the Pasteur Institute (Paris, France). C57BL/6 mice were immunized subcutaneously
with BCG (1.0  105 CFU/mouse) or TB223 (2.0  105 CFU/mouse). Six weeks after the final immunization,
mice were exposed to M. tuberculosis K for 60 min in the inhalation chamber of an airborne infection
apparatus calibrated to deliver a predetermined dose (Glas-Col, Terre Haute, IN). To confirm the initial
bacterial burden, four mice were euthanized 1 day later, and lung homogenates were plated to confirm
that approximately 200 viable bacteria were delivered to the lungs of each mouse. After 4 and 8 weeks
postchallenge, levels of protection were determined by the quantification of bacterial CFU in lung and
spleen homogenates. For histology analyses, the left lung lobes were fixed by intratracheal perfusion
with 4% formaldehyde for 24 h and were embedded in paraffin. Lung lobes were sectioned (thickness,
4 m) and were stained with hematoxylin and eosin for the histological-morphometric analysis.
Vaccination and infection of guinea pigs. Guinea pigs (Dunkin-Hartley strain) free from pathogen-
specific infection, with a body weight of 250 to 350 g, were randomly assigned to vaccine groups. Groups
of eight guinea pigs were vaccinated once on the nape, by the subcutaneous route, with 5  104 CFU
of either the M. tuberculosis sigE fadD26 mutant or BCG Danish 1331 (as a positive control). Eight animals
remained unvaccinated as a negative-control group.
Twelve weeks after vaccination, all animals were challenged by the aerosol route with M. tuberculosis
strain H37Rv, grown in batch culture under defined conditions (33). Challenge was performed using a
contained Henderson apparatus in conjunction with an AeroMP control unit as described previously
(34–36). The challenge suspension was adjusted to deliver an estimated retained, inhaled low dose of
approximately 10 to 20 CFU to the lungs of each animal (37). The suspension of M. tuberculosis in the
nebulizer was plated onto Middlebrook 7H11 OADC selective agar in order to measure the concentration
and confirm retrospectively that the expected dose had been delivered.
Measurement of protection in guinea pigs. Protection was determined by measuring the bacterial
burden 4 weeks after challenge, when guinea pigs were killed by an overdose of intraperitoneally
delivered sodium pentobarbital. At necropsy, lungs and spleens were removed as described previously
(10). For bacterial load analysis, each tissue was homogenized in 2 ml of sterile PBS. Each tissue
homogenate was serially diluted in sterile PBS, and 100 l of each dilution was plated in duplicate onto
Middlebrook 7H11 OADC selective agar. Plates were incubated at 37°C for as long as 4 weeks. After
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incubation, colonies were enumerated (as CFU), and the concentration of bacilli per milliliter of each
sample was calculated. Bacterial load data are expressed as log10 CFU per milliliter.
Efficacy was determined by pairwise comparisons between each vaccine group and the control
group, and differences were considered statistically significant if the P value was 0.05. The bacterial
load in each group was compared using a two-sample t test.
Ethics statements. Animal studies with Beijing strain K-infected C57BL/6 mice were carried out in
accordance with the guidelines of the Korean Food and Drug Administration (KFDA; Osong, South Korea).
The experimental protocols were reviewed and approved by the Ethics Committee and Institutional
Animal Care and Use Committee (permit no. 2013-0145) of the Laboratory Animal Research Center at
Yonsei University College of Medicine (Seoul, South Korea). All other studies with mice were approved
by the Institutional Ethics Committee of the National Institute of Medical Sciences and Nutrition Salvador
Zubiran in accordance with the guidelines of the Mexican national regulations on Animal Care and
Experimentation (NOM 062-ZOO-1999; permit code PAT-973-13/15-1).
The guinea pig study was conducted according to the United Kingdom Home Office Legislation for
animal experimentation and was approved by a local ethics committee at Public Health England (Porton
Down, United Kingdom) (license no. 30-3236). Each animal was identified using subcutaneously im-
planted microchips (Plexx, the Netherlands) to enable blinding of the analyses wherever possible. Group
sizes were determined by statistical power calculations (Minitab, version 16) performed using previous
data (SD, approximately 0.5) to detect a 1.0-log10 difference in the median number of CFU per milliliter.
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